Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252
Phase of Trial: Phase II
Latest Information Update: 24 Dec 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms SALVO
- 19 Oct 2017 Status changed from not yet recruiting to recruiting.
- 06 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 1 Sep 2017.
- 09 Aug 2017 New trial record